Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23,13:30-17:45
Stem Cell and Regenerative Medicine New Technology Session
Stay tuned
Conference Planning
Yu Zhang:Director and Co-President of VCANBIO, Chairman of the CGT Club of Tongxieyi
13:30-13:45 Opening Remarks
Hongjia Gong: Co-founder of Hikvision, Founder of Jiadao Capital, Controlling Shareholder and Chairman of VCANBIO
Lijian Hui: President of the Cell and Gene Therapy Division, Chinese Society for Cell Biology; Professor at the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences
13:45-14:00 iPSC-Derived Hematopoietic Stem Cells and NK Cells
Qijing Li: Director of the Cell and Gene Therapy Center, Agency for Science, Technology and Research (A*STAR), Singapore
14:00-14:20 Regulatory Framework and Latest Updates of Regenerative Medical Products at Japan PMDA
Yoshiaki Maruyama: Director of the Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
14:20-14:30 Launch Session: Global Blue Book on Stem Cell Drug Industry Development
14:30-14:45 From Unregulated Wild Growth to Compliance-Driven Competition: Breaking the MSC Industry’s Cutthroat Competition Under the Dual-Track System
Yu Zhang: Director and Co-President of VCANBIO, Chairman of the CGT Club of Tongxieyi
14:45-15:25 Panel Discussion 1: Stem Cell Therapy Clinical Translation Chain — Opportunities under New Policies
Yu Zhang(Moderator):Director and Co-President of VCANBIO, Chairman of the CGT Club of Tongxieyi
Chenyan Gao: Director of the Biologics Clinical Division, Center for Drug Evaluation, National Medical Products Administration (NMPA)
Zhenbo Su: CEO of TCRCure
Yingchi Zhang: Cellular Product Qualified Person, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences; Head of Technology Transfer Office, Haihe Laboratory of Cell Ecosystem
Wensong Tan: Founder and Chairman of Shanghai Bioengine Biotechnology
Hongming Tang: Deputy Director of the National Stem Cell Translational Resource Center; Director of the Stem Cell Clinical Translational Research Office, Shanghai East Hospital, Tongji University
15:25-15:45 Break
15:45-16:00 The Clinical Leap of Gene Editing
Wensheng Wei: Professor at the School of Life Sciences, Peking University
16:00-16:15 Empowering Clinical‑Research and Translational Application of Stem‑Cell and Regenerative Medicine via the AI‑Driven Clinical‑Trial Engineering Ecosystem Community
Huan Zhou:Executive Dean of Clinical Research Hospital of Anhui Medical University,YK Healthcare Group,Chief Scientist for Clinical Trials, Hai‑Medical Hub
16:15-16:30 Multi-Organ Regeneration and Repair Based on Epithelial Tissue Stem Cells — From Evolutionary Biology to Smart Cellular Manufacturing
Wei Zuo: Chairman of Regend Therapeutics, Professor at Tongji University
16:30-16:45 ATMP and Liver Regeneration: From ex vivo to in vivo
Guoyu Pan: Chairman of Shanghai MicroZhizhuo Biotechnology
16:45-17:00 Best practices for developing stem cell therapies and overall consideration of key ancillary materials such as culture media.
Juan Hou: Dean of the ExCell Future Institute
17:00-17:45 Panel Discussion 2: Stem Cell Product Supply Chain — Opportunities for Localization
Aimee Wang(Moderator):Co-founder & CEO ,CATUG Biotechnology
Xu Chen: Founder, Chairman and President of ExCell Bio
Wei Liu: Co-founder and CEO of CytoNiche
Weihua Huang: Chairman and CEO of Yeasen Biotechnology
Jingwen Tao: Assistant to the President, Director of the AI Innovation Center, Mind-AI